Maharashtra FDA Cancels Cadila Godown Licences Over Similar Aciloc Brand Names
The Maharashtra Food and Drug Administration (FDA) cancelled sale and distribution licences of three Cadila Pharmaceuticals godowns in Pune, Nagpur, and Thane after inspections found drugs with different active ingredients sold under similar brand names, risking patient confusion. The affected products include Aciloc 150 and 300 containing ranitidine, and variants with famotidine distinguished only by a symbol. Following a Bombay High Court directive, the FDA issued fresh notices and hearings before finalizing orders, citing unsatisfactory company responses and regulatory violations.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (49/100). Lens Score 61/100.
Outlets measured: indianexpress, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (48–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
freepressjournal broke this story on 6 Oct, 02:27 pm. Other outlets followed.